Abstract
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and the third leading cause of cancer-related mortality worldwide. Conflicting results have been reported regarding the use of serum Golgi protein 73 (GP73) as a promising serum marker for the diagnosis of HCC; therefore, the aim of the present study was to provide a systematic review of the diagnostic performance of GP73 for HCC. Following a systematic review of the relevant studies, a number of indices associated with the accuracy of the diagnostic performance of GP73, including the sensitivity and specificity, were pooled using Meta Disc 1.4 software. Data were presented as forest plots, and summary receiver operating characteristic (SROC) curve analysis was used to summarize the overall test performance. Eleven studies were included in this meta-analysis. The summary estimates for serum GP73 in diagnosing HCC were as follows: Sensitivity, 77% [95% confidence interval (CI), 75–79%]; specificity, 91% (95% CI, 90–92%); positive likelihood ratio, 4.34 (95% CI, 2.19–8.59); negative likelihood ratio, 0.30 (95% CI, 0.26–0.36) and diagnostic odds ratio, 15.78 (95% CI, 6.95–35.83). The area under the SROC curve was 0.8638, and the Q index was 0.7944. Significant heterogeneity was found. This meta-analysis indicates a moderate diagnostic value of GP73 in HCC; however, further studies with rigorous design, large sample size and multiregional cooperation are required.
Highlights
Hepatocellular carcinoma (HCC) is one of the most common, aggressive solid malignancies worldwide, accounting for in excess of two‐thirds of all primary liver cancer cases [1]
The subject headings and keywords utilized in the search strategy included i) GP73: GP73, Golgi protein 73, Golgi phosphoprotein 2, Golgi membrane protein 1; and ii) HCC: HCC, hepatocellular carcinoma, liver cell carcinoma, hepatic cell carcinoma
The sensitivity observed ranged between 43 and 88.6% (Fig. 3A), while the specificity ranged between 51.8 and 97.4% (Fig. 3B); the positive likelihood ratio (PLR) was 4.34 (Fig. 3C) and the negative likelihood ratio (NLR) was 0.30 (Fig. 3D)
Summary
Hepatocellular carcinoma (HCC) is one of the most common, aggressive solid malignancies worldwide, accounting for in excess of two‐thirds of all primary liver cancer cases [1]. HCC commonly arises against a background of chronic liver disease and cirrhosis caused by hepatitis B or C virus [9]. In these patients, surveillance strategies for the detection of early HCC are necessary. AFP is considered to be the gold‐standard serum marker for the screening of patients who are at high risk of HCC, as well as for the monitoring of treatment response [10]; the clinical value of AFP has been questioned due to its low sensitivity and specificity [11]. As the overall survival of patients with cirrhosis has improved and the global incidence of HCC has continued to increase, strategies for the early detection of HCC are urgently required [12]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
